Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer

Dr. Kim, Medical Oncologists, Levine Cancer Institute, explains how anti-PD-L1/PD-1 therapies are being combined with chemotherapy and targeted therapies to treat lung cancer

Published: 08 June 2017

Recent Videos: Lung (includes NSCLC, SCLC, Mesothelioma)

video

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

Dr. Jahanzeb considers whether the results of Keynote 189 impact PDL-1 expression and patient selection

video

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

Dr. Jahanzeb offers opinion on the continuation of pemetrexed maintenance after treatment of the patient with carboplatin, pemetrexed and pembrolizumab

video

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

Dr. Jahanzeb on whether the outcomes of Keynote 42 presented at the 2018 ASCO Annual Meeting will impact his patient ...

video

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

Dr. Santos elaborates on the exciting developments coming out of the 2018 ASCO Annual Meeting

video

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

Dr. Santos considers whether Keynote 189 in metastatic non-small cell lung cancer (NSCLC) has impacted his view of PDL-1 expression ...

video

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

Dr. Santos offers opinion on continued pemetrexed maintenance following successful treatment of a patient with combination carboplatin, pemetrexed and pembrolizumab

video

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

Dr. Santos offers opinion on the benefits of using docetaxel plus ramucirumab verus docetaxel alone in 2nd line non-small cell ...

video

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses drug sequencing as a result of ...

video

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the benefits of using Cyramza (ramucirumab) ...

video

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, on whether Keynote 189 impacted view of ...

Related Videos

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

video-image

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

video-image

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

video-image

Jennie Crews, MD, MMM, FACP, on the influence of MIPS & MACRA at Seattle Cancer Care Alliance

video-image

Carrie Tompkins Stricker, PhD, RN, AOCN, on the importance of capturing all patient symptoms

video-image

Carrie Tompkins Stricker, PhD, RN, AOCN, on what Carevive is doing to encourage patient engagement

video-image

Carrie Tompkins Stricker, PhD, RN, AOCN, on the outcomes of patients engaged in their treatment

video-image

Carrie Tompkins Stricker, PhD, RN, AOCN, speaks to the importance of patient engagement

video-image

Carrie Tompkins Stricker, PhD, RN, AOCN, on the contribution of patient reported outcomes

video-image

Pamela Tobias, MS, RHIA, CHDA, on whether LVHN is utilizing predictive analytics

video-image

Pamela Tobias, MS, RHIA, CHDA, on oncology-specific EMRs & standardization of treatment plans

video-image

Pamela Tobias, MS, RHIA, CHDA, explains how EHRs can help maximize utilization of resources

video-image

Pamela Tobias, MS, RHIA, CHDA, regarding EHR data & the impact on quality and/or cost outcomes

video-image

Pamela Tobias, MS, RHIA, CHDA, offers examples of how EHRs are improving practice processes

video-image

Pamela Tobias, MS, RHIA, CHDA, considers whether EHRs are making practices more efficient

video-image

Mark Soberman, MD, MBA, FACS, on what we can learn from the 2018 ACCC Annual Meeting

video-image

Mark Soberman, MD, MBA, FACS, tells us about his goals going into the 2018 ACCC Annual Meeting

video-image

Mark Soberman, MD, MBA, FACS, speculates on the future of cost-effective, high-quality cancer care

video-image

Mark Soberman, MD, MBA, FACS, regarding innovative oncology payment models

video-image

Mark Soberman, MD, MBA, FACS, considers next generation multidisciplinary cancer care

video-image

Mark Soberman, MD, MBA, FACS, provides examples of the benefits of coordinated care

video-image

Mark Soberman, MD, MBA, FACS, on the importance of coordinated care & multidisciplinary care

video-image

Satish Shah, MD, considers the process of getting physicians in his practice to adopt the EHR

video-image

Satish Shah, MD, on how technology can ease the burden of reporting quality measures

video-image

Satish Shah, MD, regarding the important features that every oncologist should have in their EHR

video-image

Satish Shah, MD, provides examples of how EHRs are improving practice processes

video-image

Michael Seiden, MD, PhD, on the tools MSH provides to member practices to help them thrive

video-image

Michael Seiden, MD, PhD, tells us how big data is helping to advanced clinical progress

video-image

Michael Seiden, MD, PhD, regarding the workforce shortage in oncology

video-image

Michael Seiden, MD, PhD, provides opinion on innovative oncology payment models

video-image

Michael Seiden, MD, PhD, considers the problems MSH are trying to solve for oncologists

video-image

Git Patel considers how real-time symptom management can improve adherence

video-image

Git Patel analyzes the adherence problem and tools available to help solve the issue

video-image

Git Patel regarding the importance of Chronic Care Management

video-image

Git Patel explains how technology can help practices acquire more revenue

video-image

Kavita Patel, MD, MS, FACP, discusses how 340B has impacted her practice

video-image

Kavita Patel, MD, MS, FACP, regarding the impact of MACRA on payment reform

video-image

Kavita Patel, MD, MS, FACP, speculates on next generation multidisciplinary cancer care

video-image

Kavita Patel, MD, MS, FACP, provides examples of the advantages of coordinated care

video-image

Kavita Patel, MD, MS, FACP, tells us why oncologists should coordinate care

video-image

Stephen Grubbs, MD, discusses how we measure quality cancer care today

video-image

Stephen Grubbs, MD, tells us how genomics are figuring into the value-based care equation

video-image

Stephen Grubbs, MD, speculates on the future of cost-effective cancer care

video-image

Stephen Grubbs, MD, regarding value assessment tools and treatment decisions

video-image

Stephen Grubbs, MD, considers how MIPS & MACRA are transforming the delivery of cancer care

video-image

Stephen Grubbs, MD, describes the tools ASCO provides to help practices move toward value-based care

video-image

Stephen Grubbs, MD, on what ASCO is doing to help educate members about MIPS & MACRA

video-image

Bobby Green, MD, analyzes the role of health technology companies in the design of APMs

video-image

Bobby Green, MD, shares how big data can make a positive contribution to payment reform

video-image

Bobby Green, MD, regarding big data and clinical progress

video-image

Bobby Green, MD, describes how EMR data becomes real world evidence

video-image

Ann Marie Edwards on how patients have been impacted by value-based care

video-image

Ann Marie Edwards tells us how technology has impacted the delivery of value-based care

video-image

Ann Marie Edwards examines how 340B has impacted Alliance Cancer Specialists

video-image

Ann Marie Edwards offers opinion on how to thrive in today’s oncology landscape

video-image

Ann Marie Edwards considers the physician practice models poised to succeed in a value-based world

video-image

George Daneker, MD, on the role of CMS and commercial payers in delivering value-based care

video-image

George Daneker, MD, offers opinion on various cancer care models

video-image

George Daneker, MD, regarding the role of consistency in the delivery of high-quality care

video-image

George Daneker, MD, on the advantages of having all medical oncology services under one roof

video-image

Jennie Crews, MD, MMM, FACP, on embracing new value-based oncology models

video-image

Jennie Crews, MD, MMM, FACP, explains how to maintain the delivery of quality cancer care

video-image

Sibel Blau, MD, discusses how 340B has impacted Northwest Medical Specialties

video-image

Sibel Blau, MD, shares how her practice has transformed in order to participate in MACRA

video-image

Sibel Blau, MD, regarding NWMS's affiliation with the Quality Cancer Care Alliance

video-image

Sibel Blau, MD, on the possibility of consolidating or merging her practice

video-image

Sibel Blau, MD, explains how her practice has adapted to the value-based world of medical oncology

video-image

Roy Beveridge, MD, offers examples of successful & unsuccessful cancer intervention methods

video-image

Roy Beveridge, MD, considers the social determinants influencing outcomes in cancer care

video-image

Roy Beveridge, MD, tells us how interoperability is impacting the delivery of cancer care

video-image

Roy Beveridge, MD, explains how Humana works with cancer stakeholders to develop treatment models

video-image

Roy Beveridge, MD, offers opinion on the evolution of commercial payers

video-image

Roy Beveridge, MD, regarding the most cost-efficient alternative payment models

video-image

Roy Beveridge, MD, on the scale of cancer treatment management at Humana

video-image

Jamie Bachman, MPA, elaborates on the issue of compatibility and oncology-specific EHRs

video-image

Jamie Bachman, MPA, on how integrating various software into EHRs improves processes

video-image

Jamie Bachman, MPA, regarding important features that every oncologist should have in their EHR

video-image

Jamie Bachman, MPA, on the potential drawbacks associated with oncology-specific EHRs

video-image

Jamie Bachman, MPA, offers examples of how EHRs are allowing practices to improve processes

video-image

Jamie Bachman, MPA, considers whether EHRs are making practices more efficient

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting

video-image

David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Jeanny B. Aragon-Ching, MD, FACP, on response rates for erdafitinib in metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, on molecular markers in high-risk muscle-invasive bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, discusses new guidelines in treatment of metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting

video-image

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

video-image

Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML

video-image

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

video-image

Eunice Wang, MD, considers the potential impact of gilteritinib in patients with FLT3-ITD AML

video-image

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Gary D. Steinberg, MD, on whether FGFR inhibitors have the potential to be practice-changing

video-image

Bobby Green, MD, on next-generation sequencing and Flatiron's clinico-genomic database

video-image

Bobby Green, MD, shares an update on Flatiron’s clinico-genomic database

video-image

Bobby Green, MD, reflects on the 2018 ASCO Annual Meeting

video-image

Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018

video-image

Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs

video-image

Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC

video-image

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

video-image

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

video-image

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

video-image

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

video-image

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

video-image

John Leighton, MD, regarding preoperative chemotherapy in resectable pancreatic cancer

video-image

John Leighton, MD, regarding the PA.6 clinical study presented at ASCO 2018

video-image

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

video-image

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

video-image

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC

video-image

Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018

video-image

Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC

video-image

Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC

video-image

Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions

video-image

Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment

video-image

Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure

video-image

Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI

video-image

Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer

video-image

Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018

video-image

Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018

video-image

Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs

video-image

Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC

video-image

Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure

video-image

Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy

video-image

Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC

video-image

James A. Posey III, MD, on the outcomes of the LAPACT study in locally advanced pancreatic cancer

video-image

James A. Posey III, MD, comments on the impact of immunotherapy agents in pancreatic cancer

video-image

James A. Posey III, MD, discusses the unmet medical needs in pancreatic ductal adenocarcinoma

video-image

James A. Posey III, MD, offers opinion on preoperative chemotherapy in resectable pancreatic cancer

video-image

James A. Posey III, MD, on the results and implications of the PA.6 clinical trial from ASCO 2018

video-image

Ivo Abraham, PhD, RN, comments on how we can demonstrate the value of cancer treatments

video-image

Ivo Abraham, PhD, RN, outlines biosimilar pricing and reimbursement

video-image

Ivo Abraham, PhD, RN, discusses those biosimilars that are approved or close to approval

video-image

Ivo Abraham, PhD, RN, speculates on the hurdles that could prevent the adoption of biosimilars

video-image

Ivo Abraham, PhD, RN, explains the key features of a biosimilar

video-image

Randall A. Oyer, MD, considers the work being done to address disparities in healthcare

video-image

Randall A. Oyer, MD, provides information on the ACCC Immuno-Oncology Institute

video-image

Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018

video-image

Lisa Rometty on the collaboration between Watson and the VA Precision Oncology Program

video-image

Lisa Rometty shares some of the recent accomplishments of IBM's Watson

video-image

Lisa Rometty elaborates on Watson's role in clinical trial matching

video-image

Lisa Rometty regarding the impact of Watson on real-world evidence and clinical decision making

video-image

Lisa Rometty explains how augmented intelligence is helping oncologists better treat cancer patients

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms

video-image

Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care

video-image

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer

video-image

Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer

video-image

Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018

video-image

Mark Levis, MD, PhD, discusses exciting data from the 2018 ASCO Annual Meeting

video-image

Mark Levis, MD, PhD, speculates on evolving treatment considerations for FLT3 mutated AML

video-image

Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients

video-image

Mark Levis, MD, PhD, comments on measurable residual disease in relapsed/refractory AML

video-image

Mark Levis, MD, PhD, on factors influencing 1st line therapy in AML patients with FLT3 mutations

video-image

Mark Levis, MD, PhD, regarding the impact of next-generation sequencing in AML

video-image

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis

video-image

Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer

video-image

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer

video-image

Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"

video-image

Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients

video-image

Richard Goldberg, MD, on how the FIRE-3 data in CRC presented at ASCO 2018 reinforces CALGB 80405

video-image

Richard Goldberg, MD, considers the value of preoperative chemotherapy in pancreatic cancer

video-image

Richard Goldberg, MD, regarding the outcomes of the PA.6 clinical study in pancreatic cancer

video-image

Jennie Crews, MD, MMM, FACP, regarding key initiatives for the ACCC Immuno-Oncology Institute

video-image

Jennie Crews, MD, MMM, FACP, outlines the mission of the ACCC Immuno-Oncology Institute

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms

video-image

Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC

video-image

Al Benson III, MD, FACP, tells us about the outcomes of the ECOG-ACRIN study

video-image

Jennie Crews, MD, MMM, FACP, on how community oncology is embracing biomarkers

video-image

Noa Biran, MD, on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma

video-image

Noa Biran, MD, considers whether VPd is effective in relapsed multiple myeloma

video-image

Noa Biran, MD, on the logistics involved in delivering CAR-T in the BB2121 study

video-image

Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma

video-image

Noa Biran, MD, shares some of the exciting clinical advances presented at ASCO 2018

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy

video-image

Gary D. Steinberg, MD, discusses FGFR inhibitors in metastatic bladder cancer

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”

video-image

Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer

video-image

Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer

video-image

Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?

video-image

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

video-image

Real-World Evidence Compared to Randomized Clinical Trials

video-image

Real-World Evidence as a Mechanism for Patient-Centric Care

video-image

Practical Issues When Treating With Immunotherapy

video-image

Beyond PD-L1: In Search of Better Biomarkers

video-image

Evolving Immunotherapy Combinations